Skip to content

Author

N. Dhalwani

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Projected Impact of LDL-C and HbA1c Control on Cardiovascular Outcomes in ASCVD and Diabetes

Background U.S. population estimates of atherosclerotic cardiovascular disease (ASCVD) risk reduction from comprehensive cardiometabolic risk factor control remain limited among patients with ASCVD and diabetes mellitus (DM). Objectives The objective of the study was to predict 3-year reduction in composite ASCVD event...

H. Karthikeyan, Wen-Jun Fan, Ran Jin et al. · 0 citations
Nov 2026

Abstract 6765: Lipid Management Patterns and Low-Density Lipoprotein Cholesterol Goal Attainment Among Patients with High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke in the US Stratified by Race/Ethnicity

Background: Prior studies demonstrate persistent race and ethnic disparities in lipid-lowering therapy (LLT) utilization among patients with prior ischemic events. These disparities may be more pronounced in a high cardiovascular (CV) risk population without prior myocardial infarction (MI) or stroke where patients...

S. Sakhuja, Q. Chan, Corinne Brooks et al. · 0 citations
Open access Oct 2026

Sex differences in lipid management among high-risk patients without prior myocardial infarction or stroke: results from the VESALIUS-REAL global study

Women at high cardiovascular risk consistently experienced less intensive lipid management and LDL-C goal achievement compared with men, highlighting similar sex differences in risk factors and lipid management across regions and underscore the need for targeted strategies to improve implementation of guideline-directe...

Q. Chan, J. Cegla, J. Cornel et al. · 0 citations
Open access Oct 2026

Lipid management in patients with coronary artery disease at risk of a first major atherosclerotic cardiovascular event: findings from the VESALIUS-REAL global study

In this large, global, real-world study, most patients with CAD at risk of a first MACE were undertreated with LLT and did not achieve recommended LDL-C levels, highlighting substantial gaps between guideline recommendations and real-world practice.

Q. Chan, J. Cegla, J. Cornel et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness of Evolocumab in Reducing Major Adverse Cardiovascular Events: A Cohort Study.

BACKGROUND Evolocumab reduces major adverse cardiovascular events in randomized trials, but evidence of its effectiveness in real-world clinical practice remains limited. METHODS US adults with atherosclerotic cardiovascular disease who initiated evolocumab between 2017 and 2023 were identified from the Komodo Health...

Ran Jin, K. Hurwitz, N. Dhalwani et al. · 0 citations
Open access Sep 2026

Gaps in lipid management among high-risk patients without prior MI or stroke: the VESALIUS-REAL global study.

Most patients at high CV risk were not optimally managed, with low rates of LLT initiation, treatment intensification, LDL-C monitoring, and LDL-C goal attainment across 11 databases, highlighting a substantial unmet clinical need for improved guideline-based lipid management to prevent first major CV events in high-ri...

Q. Chan, J. Cegla, U. Laufs et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.